Dr. Martens Future Growth
Future criteria checks 0/6
Dr. Martens's earnings are forecast to decline at 22.7% per annum while its annual revenue is expected to grow at 1.2% per year. EPS is expected to decline by 12% per annum. Return on equity is forecast to be 14.7% in 3 years.
Key information
-22.7%
Earnings growth rate
-12.0%
EPS growth rate
| Luxury earnings growth | 10.1% |
| Revenue growth rate | 1.2% |
| Future return on equity | 14.7% |
| Analyst coverage | Good |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
Mar 27
Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet
Mar 06Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price
Feb 08Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market
Jan 21Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156
Jan 03Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156
Dec 13Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation
Oct 12Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Sep 13Returns on Capital Paint A Bright Future For Dr. Martens (LON:DOCS)
Jul 12A Look At The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Jun 02Dr. Martens (LON:DOCS) Is Investing Its Capital With Increasing Efficiency
Feb 25Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 34% Undervaluation?
Dec 17The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
Oct 02Dr. Martens (LON:DOCS) Knows How To Allocate Capital Effectively
Jul 04Why Investors Shouldn't Be Surprised By Dr. Martens plc's (LON:DOCS) 26% Share Price Surge
Jun 16Are Investors Undervaluing Dr. Martens plc (LON:DOCS) By 27%?
Mar 02Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 19% Below Its Share Price
Dec 01Are Dr. Martens plc (LON:DOCS) Investors Paying Above The Intrinsic Value?
Aug 24Investors Can Find Comfort In Dr. Martens' (LON:DOCS) Earnings Quality
Jun 24Does This Valuation Of Dr. Martens plc (LON:DOCS) Imply Investors Are Overpaying?
Apr 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 987 | N/A | N/A | N/A | 1 |
| 3/31/2026 | 925 | 63 | 80 | 154 | 7 |
| 3/31/2025 | 867 | 52 | 82 | 152 | 7 |
| 3/31/2024 | 890 | 69 | 48 | 127 | 6 |
| 9/30/2023 | 978 | 103 | 28 | 77 | N/A |
| 6/30/2023 | 989 | 116 | 27 | 77 | N/A |
| 3/31/2023 | 1,000 | 129 | 26 | 77 | N/A |
| 12/31/2022 | 979 | 153 | 65 | 108 | N/A |
| 9/30/2022 | 957 | 177 | 104 | 138 | N/A |
| 6/30/2022 | 933 | 179 | 132 | 161 | N/A |
| 3/31/2022 | 908 | 181 | 159 | 184 | N/A |
| 12/31/2021 | 867 | 118 | 129 | 151 | N/A |
| 9/30/2021 | 825 | 54 | 98 | 117 | N/A |
| 6/30/2021 | 799 | 44 | 120 | 138 | N/A |
| 3/31/2021 | 773 | 35 | 142 | 159 | N/A |
| 12/31/2020 | 747 | 61 | 156 | 175 | N/A |
| 9/30/2020 | 722 | 87 | 169 | 190 | N/A |
| 6/30/2020 | 697 | 81 | 134 | 156 | N/A |
| 3/31/2020 | 672 | 75 | 100 | 121 | N/A |
| 3/31/2019 | 454 | 17 | 39 | 56 | N/A |
| 3/31/2018 | 349 | -6 | 30 | 46 | N/A |
| 3/31/2017 | 291 | -11 | N/A | 34 | N/A |
| 3/31/2016 | 232 | -12 | N/A | 26 | N/A |
| 3/31/2015 | 235 | 0 | N/A | 20 | N/A |
| 3/31/2014 | 164 | -32 | N/A | 5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DOCS's earnings are forecast to decline over the next 3 years (-22.7% per year).
Earnings vs Market: DOCS's earnings are forecast to decline over the next 3 years (-22.7% per year).
High Growth Earnings: DOCS's earnings are forecast to decline over the next 3 years.
Revenue vs Market: DOCS's revenue (1.2% per year) is forecast to grow slower than the UK market (3.3% per year).
High Growth Revenue: DOCS's revenue (1.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DOCS's Return on Equity is forecast to be low in 3 years time (14.7%).